NCCTG phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma.

被引：0
|
作者：
Kim, G. P.
Oberg, A.
Kabat, B.
Sing, A.
Hedrick, E.
Campbell, D.
Alberts, S.
机构：
[1] N Cent Canc Treatment Grp, Rochester, MN USA
[2] Genentech Inc, San Francisco, CA 94080 USA
[3] SanofiAventis, Bridgewater, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4113
引用
收藏
页码：206S / 206S
页数：1
相关论文
共 50 条
  • [31] PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma (ACA): A North Central Cancer Treatment Group (NCCTG) randomized phase II study
    Alberts, Steven R.
    Gill, Sharlene
    Foster, Nathan
    Morton, Roscoe
    Kugier, John
    Schaefer, Paul
    Sargent, Daniel
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 240 - 241
  • [32] Phase II trial of neoadjuvant gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy in resectable pancreatic adenocarcinoma. A GEMCAD 10-03 trial
    Laquente, B.
    Conill, C.
    Fabregat, J.
    Cambray, M.
    Ayuso, J. R.
    Valls, C.
    Bombi, J. A.
    Serrano, T.
    Ferrandez, A.
    Poves, I.
    Sabater, L.
    Montagut, C.
    Rosello, S.
    Martin-Richard, M.
    Diaz-Beveridge, R.
    Rodriguez, J.
    Gallego, R.
    Garcia-Albeniz, X.
    Fernandez-Cruz, L.
    Maurel, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S416 - S416
  • [33] A phase II trial of cabozantinib and erlotinib for patients with EGFR and c-MET co-expressing metastatic pancreatic adenocarcinoma.
    Gbolahan, Olumide B.
    Sehdev, Amikar
    Shahda, Safi
    Perkins, Susan
    Korc, Murray
    Loehrer, Patrick J.
    O'Neil, Bert H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [34] Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer
    Van Cutsem, Eric
    Hidalgo, Manuel
    Canon, Jean-Luc
    Macarulla, Teresa
    Bazin, Igor
    Poddubskaya, Elena
    Manojlovic, Nebojsa
    Radenkovic, Dejan
    Verslype, Chris
    Raymond, Eric
    Cubillo, Antonio
    Schueler, Armin
    Zhao, Charles
    Hammel, Pascal
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2018, 143 (08) : 2053 - 2064
  • [35] Phase II trial of bevacizumab, irinotecan, cisplatin, and radiation as preoperative therapy in esophageal adenocarcinoma.
    Ilson, David
    Goodman, Karyn A.
    Janjigian, Yelena Yuriy
    Shah, Manish A.
    Kelsen, David Paul
    Rizk, Nabil P.
    Rusch, Valerie W.
    Wu, Abraham Jing-Ching
    Campbell, Jenny
    Capanu, Marinela
    Bains, Manjit S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [36] A phase II trial of gemcitabine, docetaxel, and bevacizumab (GDB) in metastatic pancreas cancer
    Picozzi, V. J.
    Canlas, L. A.
    Sicuro, P. L.
    Malpass, T. W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [37] Phase II study of gemcitabine and cisplatin in locally advanced or metastatic gallbladder or bile duct adenocarcinoma.
    Servienti, PJ
    Carraro, S
    Bruno, MF
    Odena, MSC
    Felci, N
    Montiel, M
    Roca, E
    Araujo, CE
    [J]. ANNALS OF ONCOLOGY, 2000, 11 : 71 - 71
  • [38] Phase I trial of biweekly S-1, leucovorin, oxaliplatin, and gemcitabine (the SLOG regimen) in metastatic pancreatic adenocarcinoma (mPDAC).
    Chiang, Nai-Jung
    Tsai, Kelvin K.
    Chen, Jen-Shi
    Yang, Shih-Hung
    Hsu, Chiun
    Shan, Yan-Shen
    Chen, Li-Tzong
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [39] Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma:: a randomized phase II trial
    Scheithauer, W
    Schüll, B
    Ulrich-Pur, H
    Schmid, K
    Raderer, M
    Haider, K
    Kwasny, W
    Depisch, D
    Schneeweiss, B
    Lang, F
    Kornek, GV
    [J]. ANNALS OF ONCOLOGY, 2003, 14 (01) : 97 - 104
  • [40] A phase II study of capecitabine, carboplatin, and bevacizumab for metastatic or unresectable gastroesophageal junction and gastric adenocarcinoma.
    Kunz, Pamela L.
    Nandoskar, Prachi
    Koontz, Michael Zach
    Ji, Hanlee
    Ford, James M.
    Balise, Raymond R.
    Kamaya, Aya
    Rubin, Daniel
    Fisher, George A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
12345